2.390USD0.00%Mkt Cap: 12.75M USDP/E: —Last update: 2026-05-22
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycli…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap12.75M USD
Enterprise Value2.62M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-33.56M USD
Revenue/Share—
Last Price2.390 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees17
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS60855D2009
Valuation
P/E (Trailing)—
P/E (Forward)-0.02
PEG—
EV/EBITDA-0.10
EV/Revenue—
P/S—
P/B0.51
EPS (TTM)-16.16
EPS (Forward)-110.50
52W Range
1.7903% of range24.20
52W High24.20 USD
52W Low1.790 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-223.64%
ROA-151.68%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-22.73M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-101.20%
Net Debt-10.13M USD
Net Debt/EBITDA0.38
Balance Sheet
Debt/Equity0.02
Current Ratio1.38
Quick Ratio1.30
Book Value/Sh4.691 USD
Cash/Share1.933 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateFeb 1, 2021
Splits
Last Split1:25
Split DateDec 1, 2025
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)21.00 USD
Target Range10.00 USD – 31.00 USD
# Analysts3
Ownership
Shares Out.5.34M
Float5.29M
Insiders0.83%
Institutions4.40%
Short Interest
Short Ratio3.1d
Short % Float6.32%
Short % Out.6.27%
Shares Short334.36K
Short (prev mo.)113.91K
Technical
SMA 502.365 (+1.1%)
SMA 2006.845 (-65.1%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)188.79K
Avg Vol (10d)325.81K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—